Novamind To Host Clinical Trial To Advance Ketamine Therapy For End-of-Life Patients
Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.
